

## Val-Ala-PAB-MMAE

## Chemical Properties

CAS No. : 1912408-92-4


Formula: C<sub>55</sub>H<sub>88</sub>N<sub>8</sub>O<sub>11</sub>

Molecular Weight: 1037.33

Keep away from moisture, Store at low temperature

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

Actual storage temperature shall be subject to the COA.



## Biological Description

Description	Val-Ala-PAB-MMAE is a drug-linker conjugate for antibody-drug conjugates (ADCs), composed of the Val-Ala-PAB cleavable linker and MMAE, a potent microtubule inhibitor. It is designed to be cleaved by Cathepsin B within cancer cells, releasing MMAE to inhibit tubulin polymerization and induce apoptosis. This mechanism reduces toxicity to normal tissues while enhancing antitumor activity.
Targets(IC50)	Microtubule Associated, Drug-Linker Conjugates for ADC

## Solubility Information

Solubility	DMSO: 80 mg/mL (77.12 mM), Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 3.3 mg/mL (3.18 mM), Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

### Preparing Stock Solutions

---

	<b>1mg</b>	<b>5mg</b>	<b>10mg</b>
1 mM	0.964 mL	4.8201 mL	9.6401 mL
5 mM	0.1928 mL	0.964 mL	1.928 mL
10 mM	0.0964 mL	0.482 mL	0.964 mL
50 mM	0.0193 mL	0.0964 mL	0.1928 mL

---

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

### Reference

Anderson, et al. Preparation of substituted pyrrolopyridine compounds as JAK inhibitors. World Intellectual Property Organization, WO2019090158 A1 2019-05-09.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481